North Point Portfolio Managers Corp OH Sells 269 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

North Point Portfolio Managers Corp OH trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,037 shares of the biopharmaceutical company’s stock after selling 269 shares during the quarter. Regeneron Pharmaceuticals comprises approximately 2.1% of North Point Portfolio Managers Corp OH’s holdings, making the stock its 24th biggest position. North Point Portfolio Managers Corp OH’s holdings in Regeneron Pharmaceuticals were worth $12,136,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. International Assets Investment Management LLC raised its stake in Regeneron Pharmaceuticals by 86,013.3% during the 3rd quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock valued at $926,078,000 after purchasing an additional 879,916 shares during the period. Worldquant Millennium Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $127,489,000. KBC Group NV lifted its holdings in shares of Regeneron Pharmaceuticals by 296.7% in the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company’s stock worth $97,338,000 after buying an additional 102,198 shares in the last quarter. Icon Wealth Advisors LLC grew its stake in Regeneron Pharmaceuticals by 18,342.0% during the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company’s stock valued at $79,874,000 after acquiring an additional 75,569 shares in the last quarter. Finally, State Street Corp grew its stake in Regeneron Pharmaceuticals by 1.3% during the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after acquiring an additional 61,277 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have commented on REGN shares. Truist Financial dropped their price objective on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Bank of America reissued an “underperform” rating and set a $565.00 price target on shares of Regeneron Pharmaceuticals in a research note on Tuesday, December 10th. BMO Capital Markets reduced their price objective on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Cantor Fitzgerald reiterated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Finally, Citigroup cut their target price on shares of Regeneron Pharmaceuticals from $895.00 to $795.00 and set a “neutral” rating for the company in a report on Tuesday, January 14th. One analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,015.38.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $675.79 on Monday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock’s fifty day moving average is $727.19 and its two-hundred day moving average is $936.01. Regeneron Pharmaceuticals, Inc. has a 52 week low of $666.25 and a 52 week high of $1,211.20. The company has a market capitalization of $74.26 billion, a PE ratio of 16.72, a price-to-earnings-growth ratio of 1.59 and a beta of 0.10.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.